
|Videos|March 17, 2022
Dr. Min Dong discusses ongoing research with onabotulinumtoxinA for patients with urologic disease
Author(s)Urology Times staff
“Botox has been a wonderful drug for many, many years,” says Min Dong, MD.
Advertisement
In this video, Min Dong, MD, summarizes the ongoing and future research related to Botox therapies for urologic diseases. These ideas stem from the talk he gave at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting, titled, “New frontiers in therapeutic toxins for urologic disease.” Dong is an associate professor of urology at Harvard Medical School in Cambridge, Massachusetts.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












